Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 484 of 5804
-
New HIV prevention shot could last 4 months
Prevention OngoingThis study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
Phase: PHASE2 • Sponsor: ViiV Healthcare • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
Blue light surgery may slash bladder cancer recurrence
Disease control Recruiting nowComparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. En…
Phase: PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief TerminatedThe goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The main questions it aims to answer are: * Does ARD-101 improve the total score o…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Prenatal vitamin d: a simple step to stop childhood asthma?
Prevention Recruiting nowThe overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that supplementation in higher doses than recommended could redu…
Phase: PHASE3 • Sponsor: Professor Klaus Bønnelykke • Aim: Prevention
Last updated Jun 27, 2026 07:52 UTC
-
Immune-Boosting drug could help fight High-Risk thyroid cancer before surgery
Disease control Recruiting nowThis window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
Phase: PHASE2 • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New cocktail aims to tame rare blood cancer
Disease control Recruiting nowThe purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail aims to shrink untreatable liver tumors
Disease control OngoingThe main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Phase: PHASE2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Tailored drug strategy aims to keep myeloma in check after transplant
Disease control Recruiting nowThis study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate effic…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy aims to boost immune attack on tough breast cancer
Disease control Recruiting nowThis study aims to explore the best combination patterns of radiotherapy and immunotherapy for advanced triple-negative breast cancer (TNBC).
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for rare ovarian cancer? drug trial targets Hard-to-Treat clear cell tumors
Disease control Recruiting nowThe purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometrio…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Electric field therapy before brain tumor surgery shows promise in early trial
Disease control Recruiting nowPreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required…
Phase: NA • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New heart failure drug aims to cut hospitalizations and deaths
Disease control Recruiting nowThe purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered immune cells aim to keep HIV in check without daily pills
Disease control Recruiting nowHuman immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS). Treatment of HIV-1 infection with combination anti-retroviral therapy (ART) suppresses HIV-1 replication to undetectable viral levels and …
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could six months of immunotherapy be enough for melanoma? major trial launches
Disease control Recruiting now1. Rational Every year, around 5,000 people in Sweden are diagnosed with malignant skin melanoma. In the early stages of malignant skin melanoma, the chance of cure with surgery is very good. At a later stage, when the melanoma has become thick and/or has spread, the risk of recu…
Phase: PHASE3 • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New program aims to curb HIV and opioid crises with peer support and rapid access
Prevention Recruiting nowThe US opioid overdose epidemic has been accompanied by an increase in human immunodeficiency (HIV) among persons who inject drugs. HIV pre-exposure prophylaxis (PrEP) is an FDA approved medication taken daily orally by individuals who are HIV negative, but who are at increased r…
Phase: NA • Sponsor: Boston Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
Promising new attack on tough breast cancer brain metastases
Disease control Recruiting nowThis is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could brain cell implants ease Parkinson's? new trial begins
Disease control Recruiting nowThe Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States
Phase: PHASE1, PHASE2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill could ease diabetic nerve pain for good
Symptom relief OngoingThe purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New daily pill shows promise for weight loss in phase 2 trial
Disease control CompletedThis is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg…
Phase: PHASE2 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug aims to replace IVIg for nerve disease
Disease control OngoingThe main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More info…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC